The manufacturing facility is the third location, besides New Jersey and Los Angeles facilities, at which Dendreon will produce Provenge (sipuleucel-T).
The Atlanta facility includes 36 workstations, and Dendreon will bring these new workstations online in a staged approach.
Provenge (sipuleucel-T) is indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (CRPC).
The drug is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers.
Provenge was approved based on three Phase 3 studies, including the pivotal, 512-patient Phase 3 Impact study, which showed that Provenge demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic CRPC.
The trial showed Provenge extended median survival by 4.1 months compared to control.
Results from the similarly designed Phase 3 Study D9901 in asymptomatic metastatic CRPC also demonstrated a survival advantage of similar clinical magnitude as the Impact study.